Gujarat Themis Biosyn
NSE: GUJTHEM · ISIN INE942C01045 · Healthcare
₹377.15−6.80 (−1.77%)
Monday 9 November, 12:44 IST. Delayed. Source: Yahoo Finance.
Price chart
₹377.15 −6.80 (−1.77%) today
The day
- Previous close
- ₹383.95
- Open
- ₹383.95
- Day high
- ₹386.85
- Day low
- ₹376.75
Listed on NSE since 25 February 2025.
Key numbers
- Market value
- ₹4,997.17 Cr
- P/E (trailing)
- 85.89
- EPS (trailing)
- ₹4.47
- Price to book
- 14.54
- Dividend yield
- 0.18%
- Debt to equity
- 0.56
- Profit margin
- 28.0%
- Beta
- 0.67
- Volume today
- 29,104
- Average volume
- 4.21 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹148.13 Cr | ₹57.97 Cr |
| FY24 | ₹169.82 Cr | ₹59.16 Cr |
| FY25 | ₹150.79 Cr | ₹48.77 Cr |
| FY26 | ₹165.81 Cr | ₹46.68 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | ₹44 Cr | ₹11 Cr | – |
Source: Gujarat Themis Biosyn’s results filed with NSE, consolidated (the whole group). Net profit is the share of Gujarat Themis Biosyn’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
No balance sheet is on file with NSE for this company yet; companies file one every September and March.
About Gujarat Themis Biosyn
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals, medicinal chemicals, and active pharmaceutical ingredients in India and internationally. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O, an antibiotic for the treatment of traveller's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Mumbai
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Gujarat Themis Biosyn in the last day or two.
Dividends and corporate actions
All companies- Dividend - Re 0.67 Per Share
Dividend · ex-date 23 September 2026
- Dividend - Re 0.67 Per Share
Dividend · ex-date 4 September 2025 · record date 5 September 2025
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.